The effect of HESA-A on psoriasis vulgaris

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages 559-561

  Ahmadi, Amrollah ^a   Barikbin, Babak ^b   Naseri, Mohsen ^c   Mohagheghi, Mohammadali ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHED UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HESA A PREPARATION; HESA-A PREPARATION; PLANT MEDICINAL PRODUCT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IRAN; MALE; PHYTOTHERAPY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRAN; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; PSORIASIS; TABLETS;

EID: 47249144049     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mehrabi D, DiCarlo JB, Soon SL, McCall CO. Advances in the management of psoriasis: monoclonal antibody therapies. Int J Dermatol. 2002;41:827-835. (Pubitemid 36075217)
2. Greaves MW, Weinstein GP. Treatment of psoriasis. N Engl J Med. 1995;332:581-588.
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical disease. J Am Acad Dermatol 1999;41:401-407. (Pubitemid 29418506)
4. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-537. (Pubitemid 27475070)
5. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25-31. (Pubitemid 46410639)
6. Abe M, Ishibuchi H, Syuto T, et al. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris. J Dermatol. 2007;34:290-293. (Pubitemid 46535948)
7. Berends MA, Driessen RJ, Langewouters AM, et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat. 2007;18:76-83. (Pubitemid 46801841)
8. Ashcroft DM, Li Wan Po A, Griffiths CEM. Therapeutic strategies for psoriasis. J Clin Pharmacol Ther. 2000;25:1-10. (Pubitemid 30175546)
9. Ahmadi A, Hajhashemi V, Balali M. Toxicological Studies on an Anticancer Drug (HESA-A) with Marine origin. Med J Islam Acad Sci. 2001;14:145-149.
10. Ahmadi A, Sadeghi-Aliabadi H. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru. 2003;11:3.
11. Sadeghi Aliabadi H, Ahmadi A. Cytotoxicity and antitumor properties of a marine compound on cancer cells (HESA-A). Medical Journal of the Islamic Academy of Sciences. 2001;13:55-61.
12. Ahmadi A, Mohgheghi MA, Sharif-Tabrizi A. Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. Proceedings of the First National Congress on Cancer Research, Orumiah, Iran, 2001;5-8.
13. Ahmadi A, Naderi G, Asgary S. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005;31:1-6. (Pubitemid 40461565)
14. Gottieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19-34.
15. Tse TW. Use of common Chinese herbs in the treatment of psoriasis. Clin Exp Dermatol. 2003;28: 469-475. (Pubitemid 37100542)
16. Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaquetype psoriasis. Dermatology. 2007;214:155-161.